{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Absolute+Bioavailability",
    "query": {
      "condition": "Absolute Bioavailability"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 66,
    "total_pages": 7,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Absolute+Bioavailability&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-05T13:07:19.831Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03846843",
      "title": "OCR002-SP103 - Oral Immediate Release Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Cirrhosis"
      ],
      "interventions": [
        {
          "name": "OCR-002 IR Oral Tablet",
          "type": "DRUG"
        },
        {
          "name": "OCR-002 Oral Solution",
          "type": "DRUG"
        },
        {
          "name": "OCR-002 IV Solution",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ocera Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 30,
      "start_date": "2016-08-15",
      "completion_date": "2017-12-31",
      "has_results": false,
      "last_update_posted_date": "2021-09-20",
      "last_synced_at": "2026-09-05T13:07:19.831Z",
      "location_count": 1,
      "location_summary": "Coronado, California",
      "locations": [
        {
          "city": "Coronado",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03846843"
    },
    {
      "nct_id": "NCT04924140",
      "title": "A Study to Assess Absolute Bioavailability of Aducanumab in Healthy Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "Aducanumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Biogen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "40 Years to 70 Years"
      },
      "enrollment_count": 30,
      "start_date": "2021-06-30",
      "completion_date": "2021-10-01",
      "has_results": false,
      "last_update_posted_date": "2023-04-13",
      "last_synced_at": "2026-09-05T13:07:19.831Z",
      "location_count": 2,
      "location_summary": "Anaheim, California • South Miami, Florida",
      "locations": [
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "South Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04924140"
    },
    {
      "nct_id": "NCT00520169",
      "title": "Absolute Bioavailability and Nasopharyngeal Absorption of Intranasal Ketamine",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "intranasal ketamine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Javelin Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 32,
      "start_date": "2007-07",
      "completion_date": "2007-09",
      "has_results": false,
      "last_update_posted_date": "2008-01-10",
      "last_synced_at": "2026-09-05T13:07:19.831Z",
      "location_count": 1,
      "location_summary": "Cambridge, Massachusetts",
      "locations": [
        {
          "city": "Cambridge",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00520169"
    },
    {
      "nct_id": "NCT06180954",
      "title": "A Study of Carbon-14-Labelled [14C] LOXO-305 (Pirtobrutinib) in Healthy Male Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "[14C]-LOXO-305",
          "type": "DRUG"
        },
        {
          "name": "LOXO-305",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "MALE",
        "summary": "18 Years to 55 Years · Male only"
      },
      "enrollment_count": 9,
      "start_date": "2020-09-23",
      "completion_date": "2020-11-06",
      "has_results": true,
      "last_update_posted_date": "2025-01-13",
      "last_synced_at": "2026-09-05T13:07:19.831Z",
      "location_count": 1,
      "location_summary": "Madison, Wisconsin",
      "locations": [
        {
          "city": "Madison",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06180954"
    },
    {
      "nct_id": "NCT02782975",
      "title": "Absolute Bioavailability of a Single, Fixed Subcutaneous Dose of Aducanumab in Healthy Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Alzheimer's Disease"
      ],
      "interventions": [
        {
          "name": "aducanumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Biogen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 28,
      "start_date": "2016-05",
      "completion_date": "2016-11",
      "has_results": false,
      "last_update_posted_date": "2017-01-13",
      "last_synced_at": "2026-09-05T13:07:19.831Z",
      "location_count": 2,
      "location_summary": "Evansville, Indiana • Dallas, Texas",
      "locations": [
        {
          "city": "Evansville",
          "state": "Indiana"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02782975"
    },
    {
      "nct_id": "NCT01875939",
      "title": "Phase I, Open Label,Crossover Food-Effect and Absolute Bioavailability Study of WCK2349 and WCK771 in Healthy Adult Human Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Effect of Food"
      ],
      "interventions": [
        {
          "name": "Oral WCK2349",
          "type": "DRUG"
        },
        {
          "name": "IV WCK771",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Wockhardt",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 12,
      "start_date": "2013-06",
      "completion_date": "2013-06",
      "has_results": false,
      "last_update_posted_date": "2013-08-22",
      "last_synced_at": "2026-09-05T13:07:19.831Z",
      "location_count": 1,
      "location_summary": "Austin, Texas",
      "locations": [
        {
          "city": "Austin",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01875939"
    },
    {
      "nct_id": "NCT02676830",
      "title": "Evaluation of Absorption, Metabolism, and Excretion and Estimation of the Absolute Bioavailability of K-312",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Dyslipidemia"
      ],
      "interventions": [
        {
          "name": "K-312 100 mg",
          "type": "DRUG"
        },
        {
          "name": "K-312 100 ug C14 IV",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Kowa Research Institute, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "25 Years",
        "maximum_age": "45 Years",
        "sex": "MALE",
        "summary": "25 Years to 45 Years · Male only"
      },
      "enrollment_count": 13,
      "start_date": "2014-08",
      "completion_date": "2015-04",
      "has_results": false,
      "last_update_posted_date": "2016-02-18",
      "last_synced_at": "2026-09-05T13:07:19.831Z",
      "location_count": 1,
      "location_summary": "Madison, Wisconsin",
      "locations": [
        {
          "city": "Madison",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02676830"
    },
    {
      "nct_id": "NCT04454918",
      "title": "Study to Assess Absolute Bioavailability (ABA) of TAK-906 and to Characterize Mass Balance, Pharmacokinetics (PK), Metabolism, and Excretion of [14C]-TAK-906 in Healthy Male Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "TAK-906 Oral Capsule",
          "type": "DRUG"
        },
        {
          "name": "[14C]-TAK-906 Intravenous Infusion",
          "type": "DRUG"
        },
        {
          "name": "[14C]-TAK-906 Oral Solution",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Millennium Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": "55 Years",
        "sex": "MALE",
        "summary": "19 Years to 55 Years · Male only"
      },
      "enrollment_count": 6,
      "start_date": "2020-07-30",
      "completion_date": "2020-09-30",
      "has_results": true,
      "last_update_posted_date": "2022-03-07",
      "last_synced_at": "2026-09-05T13:07:19.831Z",
      "location_count": 1,
      "location_summary": "Lincoln, Nebraska",
      "locations": [
        {
          "city": "Lincoln",
          "state": "Nebraska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04454918"
    },
    {
      "nct_id": "NCT02531971",
      "title": "Fentanyl Patch Pharmacokinetics in Healthy Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Peer Review, Research"
      ],
      "interventions": [
        {
          "name": "Intravenous fentanyl citrate",
          "type": "DRUG"
        },
        {
          "name": "Duragesic®",
          "type": "DRUG"
        },
        {
          "name": "Mylan generic fentanyl",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Maryland, Baltimore",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 24,
      "start_date": "2016-01-14",
      "completion_date": "2018-10-16",
      "has_results": true,
      "last_update_posted_date": "2020-03-26",
      "last_synced_at": "2026-09-05T13:07:19.831Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02531971"
    },
    {
      "nct_id": "NCT04833049",
      "title": "Study to Evaluate Absorption, Metabolism, and Excretion, of TAK-994 in 6 Healthy Male Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "TAK-994 Oral Tablet",
          "type": "DRUG"
        },
        {
          "name": "[14C]TAK-994 Intravenous Infusion",
          "type": "DRUG"
        },
        {
          "name": "[14C]TAK-994 Oral Suspension",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Takeda",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": "55 Years",
        "sex": "MALE",
        "summary": "19 Years to 55 Years · Male only"
      },
      "enrollment_count": 6,
      "start_date": "2021-04-14",
      "completion_date": "2021-06-20",
      "has_results": false,
      "last_update_posted_date": "2021-06-29",
      "last_synced_at": "2026-09-05T13:07:19.831Z",
      "location_count": 1,
      "location_summary": "Lincoln, Nebraska",
      "locations": [
        {
          "city": "Lincoln",
          "state": "Nebraska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04833049"
    }
  ]
}